CVRx (NASDAQ:CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with chronic heart failure and drug-resistant hypertension. The company’s proprietary Barostim® system delivers controlled electrical pulses to the carotid baroreceptors, aiming to modulate autonomic nervous system activity and improve cardiovascular function. Barostim therapy is designed as an adjunct to standard of care, offering a novel approach for patients who have exhausted pharmacological options or who remain symptomatic despite optimized medical management.
The flagship product, Barostim neo®, consists of a small implantable pulse generator, a lead placed along the carotid artery, and a patient programmer. The system is surgically implanted under local anesthesia, enabling clinicians to tailor stimulation parameters for individual patient needs. Clinical studies have demonstrated improvements in blood pressure control, exercise capacity and quality of life measures, underpinning regulatory clearances in Europe for both hypertension and heart failure indications.
Founded in Minneapolis, Minnesota, CVRx has steadily expanded its footprint since securing CE mark approval for hypertension in 2011. The company has since achieved a series of regulatory milestones, including CE mark extension for heart failure, and is actively pursuing U.S. Food and Drug Administration approval through ongoing pivotal trials. CVRx has established distribution partnerships and clinical centers of excellence across Europe, Asia-Pacific and the Middle East, fostering real-world adoption and academic collaboration to broaden the therapeutic reach of baroreflex activation therapy.
Under the leadership of CEO Kevin Hykes and a management team with deep experience in cardiovascular device development, CVRx continues to invest in research and development. Headquartered in Minneapolis, the company leverages global R&D and manufacturing capabilities to advance its pipeline, explore new neuromodulation applications and support physicians and patients worldwide in achieving improved clinical outcomes.
